Navigation Links
What patients want: A story of choice, clinical trials & evidence-based medicine

Clinical trials are serious business. In addition to being big business (untold billions of dollars every year), they also involve serious ethical issues and choices. We are all aware of the fundamental ethical principle of informed consent underlying all clinical trials.

What is less obvious is that co......

Full article >>> A Randomized Trial summarized this important clinical trial. They were also accompanied by two editorials and the trial results were significant enough to raise the attention of the national media, including an article in the New York Times - Study Ques......

Full article >>> the extremely high numbers of crossovers (45 to 60 percent of patients) and, to a lesser extent, a certain degree of missing data, such analyses are significantly confounded and should not be used to compare different strategies, as Dr. David Flum, a contributing editor at JAMA, wrote in his accompanying editorial.

Instea......

Full article >>> e? Where their pain thresholds higher yet their risk tolerance less? While the study yielded indefinite results, this much is for sure: patients want (and certainly act upon) choice.

It was a bit disappointing then to read further in the JAMA editorials that designing clinical trials with sham-controlled surgeries (e.g. operations in which the patient is cut but the actual restorative pr......

Full article >>> s="AuthorBio">Dr. Ogan Gurel is chairman of the Aesis Research Group, which provides forward-looking information and research services to the healthcare and life sciences investment community. Gurel was previously CEO of Duravest, a publicly traded Chicago investment company that initiates and develops next-generation medical technologies. Previous to Duravest, he was a vice president and medical ......

Full article >>>
'"/>

Source:wistechnology.com By Ogan Gurel 03/19/07


Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Heart patients benefit from digital image network
3. RNA Interference and Gene Silencing: History and Overview
4. Google to place Wisconsin history online
5. The world of in-vitro diagnostics is another Midwest success story
6. The world of in vitro diagnostics is another Midwest success story
7. The end of technology history
8. Carl Christensen says Marshfield Clinics history gives it an IT edge
9. An entrepreneurial success story Frank Langley champions biocapitalism
10. When its parts pull together, Wisconsin can tell a compelling economic story
11. Berbees success is based on companys history and culture
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):